BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial...

BioLineRx与Ayrmid签署了关于Motixafortide（在美国商业名称为Aphexda）的许可协议。BioLineRx将收到1000万美元的预付款，并有资格获得高达8700万美元的潜在商业...

Benzinga · 2024/11/21 19:33

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.
BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.
BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.
BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.
Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –

Aphexda是Biolinerx经美国食品药品管理局批准的干细胞动员剂，适用于多发性骨髓瘤患者的采集和随后的自体移植。
BioLinerX将从Ayrmid Ltd.（Gamida Cell的母公司）获得1000万美元的预付款，外加高达8700万美元的商业里程碑，以及净销售额从18％到23％不等的特许权使用费。
BioLinerX保留开发和商业化用于实体瘤（包括PDAC）的莫沙福肽的权利。
BioLinerX从Highbridge Capital Management, LLC管理的某些基金中获得了900万美元的股权投资，以支持公司的管道和扩张。
交易使BioLinerX能够显著减少运营费用和债务，并使公司能够专注于肿瘤学和罕见疾病领域未得到满足的高需求领域的开发活动—

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息